

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM804256

|   |   |  |                       |
|---|---|--|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                                    |  |                       |
| <b>NATURE OF CONVEYANCE:</b>  | TRADEMARK SECURITY AGREEMENT                      |  |                       |
| <b>CONVEYING PARTY DATA</b>   |   |  |                       |
| <b>Name</b>   | <b>Formerly</b>                                   | <b>Execution Date</b>                    | <b>Entity Type</b>    |
| BIOCRYST<br>PHARMACEUTICALS, INC.   |   | 04/17/2023                               | Corporation: DELAWARE |
| <b>RECEIVING PARTY DATA</b>   |   |  |                       |
| <b>Name:</b>  | BIOPHARMA CREDIT PLC                              |  |                       |
| <b>Street Address:</b>  | C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD             |  |                       |
| <b>City:</b>  | EXETER EX4 4EP                                    |  |                       |
| <b>State/Country:</b>   | UNITED KINGDOM                                    |  |                       |
| <b>Entity Type:</b>   | Private Limited Company: ENGLAND AND WALES        |  |                       |
| <b>PROPERTY NUMBERS Total: 11</b>   |   |  |                       |
| <b>Property Type</b>  | <b>Number</b>                                     | <b>Word Mark</b>                         |                       |
| <b>Registration Number:</b>   | 3974837   | BIOCRYST                                 |                       |
| <b>Registration Number:</b>   | 5713814   | BIOCRYST                                 |                       |
| <b>Registration Number:</b>   | 6502554   | BIO CRYST                                |                       |
| <b>Registration Number:</b>   | 5549799   | BIO CRYST                                |                       |
| <b>Registration Number:</b>   | 2902002   | BIOCRYST PHARMACEUTICALS, INC.           |                       |
| <b>Registration Number:</b>   | 3974836   | BIOCRYST PHARMACEUTICALS, INC.           |                       |
| <b>Registration Number:</b>   | 5549798   | DELIVERING EXTRAORDINARY. EMPOWERING ORD |                       |
| <b>Registration Number:</b>   | 6403863   | ORLADEYO                                 |                       |
| <b>Registration Number:</b>   | 6068696   | TOGETHER AS ONE                          |                       |
| <b>Registration Number:</b>   | 6608643   |  |                       |
| <b>Registration Number:</b>   | 6502555   |  |                       |
| <b>CORRESPONDENCE DATA</b>  |   |  |                       |
| <b>Fax Number:</b>  | 2028874288  |  |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |   |  |                       |
| <b>Phone:</b>   | 2028874000  |  |                       |
| <b>Email:</b>   | mbeyene@akingump.com, DC_IPDocketing@AKINGUMP.com |  |                       |
| <b>Correspondent Name:</b>  | Mussie B Beyene                                   |  |                       |
| <b>Address Line 1:</b>  | 2001 K Street N.W.                                |  |                       |
| <b>Address Line 4:</b>  | Washington DC, D.C. 20006                         |  |                       |

CH \$290.00 3974837

|                                |                   |
|--------------------------------|-------------------|
| <b>ATTORNEY DOCKET NUMBER:</b> | 687747.0071       |
| <b>NAME OF SUBMITTER:</b>      | Mussie B Beyene   |
| <b>SIGNATURE:</b>              | /Mussie B Beyene/ |
| <b>DATE SIGNED:</b>            | 04/19/2023        |

**Total Attachments: 5**

source=Pharmakon - BioCryst -- Trademark Security Agreement [EXECUTED]#page1.tif  
source=Pharmakon - BioCryst -- Trademark Security Agreement [EXECUTED]#page2.tif  
source=Pharmakon - BioCryst -- Trademark Security Agreement [EXECUTED]#page3.tif  
source=Pharmakon - BioCryst -- Trademark Security Agreement [EXECUTED]#page4.tif  
source=Pharmakon - BioCryst -- Trademark Security Agreement [EXECUTED]#page5.tif

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT, dated as of April 17, 2023, is made by BIOCRYST PHARMACEUTICALS, INC. ("Grantor"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of April 17, 2023 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation ("Borrower"), the other parties thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, as Collateral Agent, BPCR LIMITED PARTNERSHIP, (as a "Lender") and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a "Lender"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of April 17, 2023 in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Trademark Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Trademark Collateral"):

(a) all of its Trademarks and all of its rights under IP Licenses and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Trademark, including, without limitation, those referred to on Schedule 1 hereto, but excluding any "intent-to-use" application for registration of a United States Trademark for which a "Statement of Use" pursuant to Section 1(d) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) or an "Amendment to Allege Use" pursuant to Section 1(c) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) has not been filed with and accepted by the Applicable IP Office (but only excluding such intent-to-use application until such statement of use or amendment to allege use (as applicable) is filed with and accepted by the Applicable IP Office);

(b) all renewals and extensions of the foregoing;

(c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

(d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Trademarks and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Trademark Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN TRADEMARK COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.


THE TERMS OF SECTION 10 OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.

Section 7. Termination. Upon the absolute, unconditional and irrevocable payment in full of the Secured Obligations in accordance with the provisions of the Loan Agreement and the expiration or termination of the Term Loan Commitments, the security interest in the Trademark Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and all rights to the Trademark Collateral shall automatically revert to Grantors or any other Person entitled thereto. At such time, the Collateral Agent authorizes the filing by such Grantor of an appropriate termination hereof.

Section 8. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the security interest granted pursuant to this Trademark Security Agreement, the terms of this Trademark Security Agreement and the exercise of any right or remedy hereunder are subject to the provisions of the Intercreditor Agreement, dated as of November 19, 2021, by and between the Collateral Agent (as successor to Athyrium Opportunities III Co-Invest 1 LP), RPI 2019 Intermediate Finance Trust (“RPI”), OCM IP Healthcare Holdings Limited (“OMERS”), as amended by the Amendment to the Intercreditor Agreement, dated as of April 17, 2023, by and among the Collateral Agent, RPI and OMERS, and acknowledged and agreed to by Borrower and each Credit Party (as may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time).

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,  
BIOCRYST PHARMACEUTICALS, INC.  
as Grantor


DocuSigned by:  
  
By: \_\_\_\_\_  
4F25BB5FD4CA4BC...  
Name: Anthony J. Doyle  
Title: Chief Financial Officer

ACCEPTED AND AGREED  
as of the date first above written:





BIOPHARMA CREDIT PLC,  
as Collateral Agent

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By:   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member

**Schedule 1**  
US Trademarks

| Country | Mark  | Filing/Reg. Date | Serial/Reg. No. | Status     | Owner                          |
|---------|---|------------------|-----------------|------------|--------------------------------|
| U.S.    | BIOCRYST  | 6/7/2011         | 3,974,837       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | BIOCRYST  | 4/2/2019         | 5,713,814       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    |    | 9/28/2021        | 6,502,554       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    |    | 8/28/2018        | 5,549,799       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | BIOCRYST<br>PHARMACEUTICALS,<br>INC.  | 11/9/2004        | 2,902,002       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | BIOCRYST<br>PHARMACEUTICALS,<br>INC.  | 6/7/2011         | 3,974,836       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | DELIVERING<br>EXTRAORDINARY.<br>EMPOWERING<br>ORDINARY.                             | 8/28/2018        | 5,549,798       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | ORLADEYO  | 6/29/2021        | 6,403,863       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    | TOGETHER AS ONE   | 6/2/2020         | 6,068,696       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    |  | 1/4/2022         | 6,608,643       | Registered | BioCryst Pharmaceuticals, Inc. |
| U.S.    |  | 9/28/2021        | 6,502,555       | Registered | BioCryst Pharmaceuticals, Inc. |